|
|
April 29, 2021
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attn: Jason Drory, Office of Life Sciences
| Re: | Catalyst Biosciences, Inc. Registration Statement on Form S-3 Filed March 4, 2021 File No. 333-253874 REQUEST FOR ACCELERATION OF EFFECTIVENESS |
Acceleration Request
| Requested Date: | May 3, 2021 | |||
| Requested Time: | 4:00 p.m. Eastern Time |
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Catalyst Biosciences, Inc. (the “Company”) hereby requests that the Securities and Exchange Commission (the “Commission”) take appropriate action to declare the Company’s Registration Statement on Form S-3 (File No. 333-253874) effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.
The Company hereby authorizes Stephen Thau, who is an attorney with the Company’s outside legal counsel, Orrick, Herrington & Sutcliffe LLP, to orally modify or withdraw this request for acceleration.
The Company requests that it be notified of such effectiveness by a telephone call to Mr. Thau at (212) 506-5076.
[Signature page follows]
| Sincerely, | ||
| CATALYST BIOSCIENCES, INC. | ||
| By: | /s/ Clinton Musil | |
| Name: Clinton Musil | ||
| Title: Chief Financial Officer | ||
| cc: | Nassim Usman, Ph.D., Catalyst Biosciences, Inc. |
Stephen Thau, Esq., Orrick, Herrington & Sutcliffe LLP